Skip to main content

Table 7 Distribution of the study population according to methylation level of the CpG located in the enhancer

From: Case–control study of HLA-G promoter methylation status, HPV infection and cervical neoplasia in Curitiba, Brazil: a pilot analysis

CpG (enhancer)* Cases Controls
  N = 96 N = 76
  N % N %
Mean methylation <33 % 37 38.5 40 52.6
Mean methylation >33 % 59 61.5 36 47.4
  1. *CpG site position 598 (GenBank: J03027.1).